# Werewolf Therapeutics to Merge with Ambros in Reverse Deal, Raising $150 Million for Rare Disease Drug


## Key Takeaways

- Werewolf Therapeutics, a publicly traded entity, is undergoing a reverse merger with Ambros Therapeutics, a private company, to facilitate Ambros's access to public capital markets.
- Ambros Therapeutics has secured $150 million in funding, which will be primarily allocated to advancing its lead rare disease drug candidate through Phase 3 clinical trials and preparing for regulatory submission.
- The strategic maneuver addresses Werewolf Therapeutics' previously announced review of strategic alternatives, effectively resolving its market positioning challenges.
- This transaction highlights the financial challenges inherent in rare disease drug development, where high costs are compounded by limited patient populations, necessitating significant capital infusion for late-stage progression.
- The reverse merger structure allows Ambros to bypass a traditional Initial Public Offering (IPO) process, leveraging Werewolf's existing public listing for capital acquisition and market presence.

---

Werewolf Therapeutics has ended its search for strategic alternatives. The company has agreed to merge with Ambros Therapeutics in an all-stock reverse merger. Ambros has raised $150 million in connection with the deal. The combined company will use the funds to advance its lead rare disease drug candidate through Phase 3 trials and toward a regulatory filing for approval.

Reverse mergers allow a private company to take over a public company’s listing, providing access to public markets without a traditional initial public offering. For Ambros, the deal supplies capital to support a late-stage clinical program in a rare disease, an area where development costs are high and patient populations are small. The transaction also resolves Werewolf’s months-long review of strategic options.

Source: [original report](https://www.fiercebiotech.com/biotech/werewolf-transforming-reverse-merger-support-ambros-phase-3-push)

## Related Clinical & Scientific Guides

* [define tissue biology](/blog/news/define-tissue-biology)
* [definition tissue biology](/blog/news/definition-tissue-biology)
* [fierce biotech](/blog/news/fierce-biotech)